Clinical trials: Cerebral Disorder
Parkinson Disease
A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia
This is a Phase 2b study investigating the efficacy and safety of mesdopetam as adjunct therapy on daily ON-time without troublesome dyskinesia in patients with Parkinson disease. Mesdopetam is taken for 84 days.
- Trial name
- NCT04435431
- Testing
- Mesdopetam
- Where
- 44 sites in United States, France and 4 more
- Volunteers
- 155 people
- Sponsor
- Integrative Research Laboratories AB
Tourette's Syndrome
A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette's Syndrome
The purpose of this clinical trial is to study the therapeutic effect of tetrabenazine MR in children with Tourette's Syndrome, as measured by the improvement in total tic score of the Yale Global Tic Severity Scale (YGTSS).
- Trial name
- TBZ-MR (NCT01133353)
- Testing
- Tetrabenazine MR
- Sponsor
- Bausch Health Americas, Inc.
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa
To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled-release levodopa/carbidopa 100/25 mg…
- Trial name
- NCT02169453
- Testing
- BIA 9-1067, Sinemet® CR 100/25
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Neonatal Hypoxic-Ischemic Encephalopathy (HIE)
CoolCap Trial, Treatment of Perinatal Hypoxic-Ischemic Encephalopathy
This is a research study of head cooling. Its goal is to determine whether cooling babies' heads can reduce or prevent brain damage that may have resulted from temporarily reduced oxygen supply to the brain.
- Trial name
- NCT00383305
- Testing
- Cool-Cap
- Where
- 27 sites in United States, Canada and 2 more
- Volunteers
- 235 people
- Sponsor
- Olympic Medical
Growth Hormone Deficiency
Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)
This study assesses the safety and tolerability of weekly TV-1106 compared to daily rhGH in adults with GHD who have previously been treated with rhGH.
- Trial name
- NCT02410356
- Testing
- TV-1106, dGH
- Where
- 50 sites in United States, Austria and 6 more
- Volunteers
- 34 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Alzheimer's Disease, Healthy Participants
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease
This is a Phase 1/1b, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL921 in healthy…
- Trial name
- NCT07758595
- Testing
- DNL921
- Where
- United Kingdom
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Denali Therapeutics Inc.
Focal Epilepsy
ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures
The ENACT trial is designed to evaluate the efficacy and safety of ENX-101 administered adjunctively to current therapy in reducing seizure frequency in patients diagnosed with focal (partial onset) epilepsy and treated with 1 to…
- Trial name
- ENACT (NCT05481905)
- Testing
- ENX-101
- Where
- 38 sites in United States
- Sponsor
- Engrail Therapeutics INC
Hereditary Tyrosinemia, Type I
A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 Patients
This is a prospective, non-interventional, non-comparative, multicenter study to collect data on HT-1 patients in China treated with Nitisinone in a routine clinical setting. No tests or examinations are mandated in the study.
- Trial name
- NCT06227429
- Testing
- Nitisinone
- Where
- 4 sites in China
- Sponsor
- Swedish Orphan Biovitrum
Stroke
Study of ONO-2506 in Patients With Acute Ischemic Stroke
The purpose of this study is to determine the efficacy and safety of ONO-2506 compared to placebo in patients with acute ischemic stroke.
- Trial name
- NCT00229177
- Testing
- ONO-2506
- Where
- 9 sites in Japan
- Volunteers
- 757 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Adult Growth Hormone Deficiency
A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone Deficiency
This study investigates the safety, tolerability, pharmacokinetic profile (PK), and pharmacodynamic response (PD) of three different doses of ACP-001 given once-a-week compared to one dose-level of an approved daily human growth…
- Trial name
- NCT01247675
- Testing
- ACP-001 (TransCon hGH), Omnitrope
- Where
- 4 sites in Denmark, Germany and 2 more
- Volunteers
- 37 people
- Sponsor
- Ascendis Pharma A/S
Alzheimer's Disease, Dementia
A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease
The purpose of this study is to demonstrate the safety and efficacy of PF-01913539 in the treatment of patients with mild-to-moderate Alzheimer's Disease.
- Conditions
- Alzheimer's Disease, Dementia, Dimebon, Investigational Drug
- Trial name
- NCT01066481
- Testing
- PF-01913539 5 mg
- Sponsor
- Pfizer
Huntington's Disease
A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease
The primary purpose of this study is to assess the effect of food upon the pharmacokinetics (PK) of SEN0014196 in subjects with Huntington disease (HD).
- Trial name
- NCT01485965
- Testing
- SEN0014196
- Where
- 7 sites in United States
- Volunteers
- 26 people
- Sponsor
- Siena Biotech S.p.A.
Refractory Epilepsy
Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of 4 daily doses of RWJ-333369 as adjunctive treatment of refractory partial epilepsy in subjects who are between 18 and 70 years of age…
- Trial name
- NCT00228969
- Testing
- RWJ-333369
- Where
- 61 sites in United States, Argentina and 6 more
- Sponsor
- SK Life Science, Inc.
Alzheimer's Disease, Healthy Participants
A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration
The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with…
- Trial name
- NCT07780383
- Testing
- BMS-986446
- Where
- 6 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Cerebrovascular Disease
On-Premise and Remote Robotic Neurointervention
This study is a prospective, single arm, single-center study to evaluate the safety and feasibility of the Remedy Robot for on premise and remote robotic Neurointervention.
- Trial name
- NCT06365554
- Testing
- Remedy Robot
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Remedy Robotics, Inc.
Bardet-Biedl Syndrome (BBS), Obesity
An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)
An open-label, single-arm, multicenter, Expanded Access Protocol [EAP] designed to provide treatment access to setmelanotide (3 mg, administered subcutaneously [SC], once daily) for eligible patients with BBS who have no…
- Trial name
- NCT05183802
- Testing
- Setmelanotide, administered subcutaneously [SC], once daily.
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Partial Epilepsy
Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy
The primary objective was to evaluate the efficacy of eslicarbazepine acetate (ESL) administered once daily at 1200 mg or 800 mg, compared with placebo as adjunctive therapy in patients with refractory partial epilepsy over a…
- Trial name
- NCT00957372
- Testing
- eslicarbazepine acetate, ESL - Open-label Extension (Part II)
- Where
- Portugal
- Volunteers
- 253 people
- Sponsor
- Bial - Portela C S.A.
Alzheimer's Dementia
Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia
This phase IIIb study is intended to implement a consistent treatment way for switching to Exelon transdermal patch from oral formulation of rivastigmine to stress the importance of (1) advantages of transdermal patch over…
- Trial name
- NCT01585272
- Testing
- ENA713
- Where
- 4 sites in Taiwan
- Volunteers
- 121 people
- Sponsor
- Novartis Pharmaceuticals
Epilepsy
Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).
The objective of study is to assess the clinical improvement (change in seizure frequency), safety, and tolerability of subjects with partial seizures following adjunctive therapy of pregabalin BID (150 to 600 mg/day titration)…
- Trial name
- LEADER (NCT00288639)
- Testing
- Pregabalin
- Where
- 8 sites in Greece
- Volunteers
- 98 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Parkinson's Disease
A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients
In this Phase I/IIa study, the effect of continuous subcutaneous administration of LD/CD solution (ND0612) on the safety and PK profile of LD will be examined.
- Trial name
- NCT01725802
- Testing
- Levodopa/carbidopa solution for SC administration
- Where
- Israel
- Volunteers
- 8 people
- Sponsor
- NeuroDerm Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.